TrialNature communications2024

The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial.

David Hsiehchen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.